Myriad reports that the acquisition expands its research portfolio to include biomarkers for new disease areas such as psychiatric disorders, infections diseases and inflammatory diseases.
Rules-Based Medicine works with more than 20 pharmaceutical and biotech partners in developing new biomarkers and has operations in Texas, N.Y., and Germany.
It will operate as a wholly owned subsidiary of Myriad and be called Myriad RBM.
